Symbols / QNTM
QNTM Chart
About
Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. It operates through two segments, Biopharmaceutical Innovation and Strategic Investments. The company researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. It also develops FSD-PEA, which is in preparation for Phase 2 trial for the treatment of inflammatory diseases, such as mast cell activation syndrome; Lucid-PSYCH to treat major depressive disorder; and unbuzzd, a dietary supplement for the treatment of alcohol misuse. In addition, the company maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd. was founded in 1998 and is headquartered in Toronto, Canada.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 14.64M |
| Enterprise Value | 13.84M | Income | -28.51M | Sales | — |
| Book/sh | 2.27 | Cash/sh | 0.28 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -0.49 | PEG | — |
| P/S | — | P/B | 1.68 | P/C | — |
| EV/EBITDA | -0.74 | EV/Sales | — | Quick Ratio | 0.60 |
| Current Ratio | 1.41 | Debt/Eq | 34.06 | LT Debt/Eq | — |
| EPS (ttm) | -9.55 | EPS next Y | -7.80 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-06 16:00 | ROA | -72.22% |
| ROE | -251.26% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 3.84M |
| Shs Float | 3.58M | Short Float | 2.04% | Short Ratio | 1.16 |
| Short Interest | — | 52W High | 38.25 | 52W Low | 3.51 |
| Beta | 0.81 | Avg Volume | 104.74K | Volume | 22.82K |
| Target Price | — | Recom | None | Prev Close | $3.54 |
| Price | $3.81 | Change | 7.63% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$3.81
Latest analyst target
3. DCF / Fair value
$-40.20
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.81
Low
—
High
—
Mean
—
- INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - QNTM - ChartMill Fri, 20 Feb 2026 00
- Quantum BioPharma Ltd. Announces Corporate Updates - Yahoo Finance Wed, 29 Oct 2025 07
- Quantum Biopharma (QNTM) Alleges Stock Market Manipulation in W5 Series - GuruFocus Mon, 01 Dec 2025 08
- Quantum BioPharma Shares Surge 32% After Lawsuit Investigation News Coverage - Nasdaq Wed, 26 Nov 2025 08
- Quantum BioPharma stock falls after GameStop share purchase - Investing.com ue, 22 Jul 2025 07
- Quantum Biopharma’s USD $700 Million Lawsuit Alleging Stock - GlobeNewswire Wed, 26 Nov 2025 08
- Quantum BioPharma Moves to Lead Class Action Alleging Bank Manipulation of Its Shares - TipRanks Mon, 22 Dec 2025 08
- Quantum BioPharma Announces Closing of Private Placement & Provides Corporate Update - TMX Newsfile Wed, 10 Dec 2025 08
- Bronstein, Gewirtz & Grossman LLC Urges Quantum Biopharma Ltd. Investors to Act: Class Action Filed Alleging Investor Harm - marketscreener.com hu, 19 Feb 2026 17
- Quantum BioPharma Stock Rockets As Media Probe Shines Light On Spoofing Allegations Linked To Its $700M Lawsuit - Stocktwits Wed, 26 Nov 2025 08
- Is Quantum BioPharma (CSE:QNTM) Using Too Much Debt? - simplywall.st Sat, 09 Aug 2025 07
- Quantum BioPharma (QNTM) Offers $7M for Solid Evidence of Stock Manipulation - GuruFocus Wed, 08 Oct 2025 07
- INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines – QNTM - ChartMill ue, 17 Feb 2026 17
- Quantum BioPharma Ltd. Announces Expiration of All Warrants Held by Hedge Funds and Re-Iterates October 27, 2025, Record Date for the Distribution of a Special Dividend - GlobeNewswire Mon, 20 Oct 2025 07
- Quantum BioPharma offers $7 million reward for stock manipulation evidence - Investing.com Wed, 08 Oct 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 15 | 271.0 | — | Acquisition under a prospectus exemption at price 18.12 per share. | Durkacz (Anthony John) | 10% Security Holder of Issuer | — | 2025-12-10 00:00:00 | I |
| 1 | 15 | 271.0 | — | Acquisition under a prospectus exemption at price 18.12 per share. | Saeed (Zeeshan) | Director of Issuer | — | 2025-12-10 00:00:00 | I |
| 2 | 6967 | 68415.0 | — | Disposition in the public market at price 9.82 per share. | Carroll (Donal) | Director of Issuer | — | 2025-11-26 00:00:00 | D |
| 3 | 500 | 4739.0 | — | Disposition in the public market at price 9.48 per share. | Carroll (Donal) | Director of Issuer | — | 2025-11-26 00:00:00 | D |
| 4 | 14000 | 94220.0 | — | Disposition in the public market at price 6.73 per share. | Carroll (Donal) | Director of Issuer | — | 2025-11-25 00:00:00 | D |
| 5 | 13000 | 81250.0 | — | Disposition in the public market at price 6.25 per share. | Carroll (Donal) | Director of Issuer | — | 2025-11-24 00:00:00 | D |
| 6 | 8000 | 46880.0 | — | Disposition in the public market at price 5.86 per share. | Carroll (Donal) | Director of Issuer | — | 2025-11-21 00:00:00 | D |
| 7 | 16000 | 100480.0 | — | Disposition in the public market at price 6.28 per share. | Carroll (Donal) | Director of Issuer | — | 2025-11-20 00:00:00 | D |
| 8 | 6100 | 41358.0 | — | Disposition in the public market at price 6.78 per share. | Carroll (Donal) | Director of Issuer | — | 2025-11-18 00:00:00 | D |
| 9 | 21245 | 134480.0 | — | Disposition in the public market at price 6.33 per share. | Carroll (Donal) | Director of Issuer | — | 2025-11-18 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -14.82M | -11.34M | -22.41M | -29.65M |
| TotalUnusualItems | 439.20K | -4.39M | 287.58K | -175.98K |
| TotalUnusualItemsExcludingGoodwill | 439.20K | -4.39M | 287.58K | -175.98K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -14.20M | -17.90M | -26.70M | -33.94M |
| ReconciledDepreciation | 490.57K | 2.51M | 4.53M | 4.05M |
| EBITDA | -14.38M | -15.72M | -22.12M | -29.82M |
| EBIT | -14.87M | -18.23M | -26.65M | -33.87M |
| NetInterestIncome | 525.31K | 786.06K | 318.91K | -68.11K |
| InterestExpense | 47.58K | 299.00 | 48.82K | 69.40K |
| InterestIncome | 572.89K | 786.36K | 367.74K | 1.29K |
| NormalizedIncome | -14.64M | -13.52M | -26.99M | -33.76M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -14.20M | -17.90M | -23.61M | -35.29M |
| TotalExpenses | 15.88M | 19.57M | 27.43M | 33.74M |
| TotalOperatingIncomeAsReported | -16.14M | -23.79M | -27.43M | -33.74M |
| DilutedAverageShares | 1.14M | 609.06K | 595.88K | 537.62K |
| BasicAverageShares | 1.14M | 609.06K | 595.88K | 537.62K |
| DilutedEPS | -13.12 | -29.93 | -39.61 | -65.65 |
| BasicEPS | -13.12 | -29.93 | -39.61 | -65.65 |
| DilutedNIAvailtoComStockholders | -14.20M | -17.90M | -23.61M | -35.29M |
| NetIncomeCommonStockholders | -14.20M | -17.90M | -23.61M | -35.29M |
| NetIncome | -14.20M | -17.90M | -23.61M | -35.29M |
| MinorityInterests | 712.80K | 328.41K | 0.00 | 0.00 |
| NetIncomeIncludingNoncontrollingInterests | -14.92M | -18.23M | -23.61M | -35.29M |
| NetIncomeDiscontinuousOperations | 0.00 | 0.00 | 3.10M | -1.35M |
| NetIncomeContinuousOperations | -14.92M | -18.23M | -26.70M | -33.94M |
| PretaxIncome | -14.92M | -18.23M | -26.70M | -33.94M |
| OtherIncomeExpense | 443.19K | 553.46K | 407.04K | -126.18K |
| OtherNonOperatingIncomeExpenses | 3.99K | 4.94M | 119.45K | 49.79K |
| SpecialIncomeCharges | 732.42K | -4.56M | 0.00 | 0.00 |
| OtherSpecialCharges | -732.42K | |||
| ImpairmentOfCapitalAssets | 0.00 | 4.56M | 0.00 | 0.00 |
| GainOnSaleOfSecurity | -293.21K | 170.25K | 287.58K | -175.98K |
| NetNonOperatingInterestIncomeExpense | 525.31K | 786.06K | 318.91K | -68.11K |
| InterestExpenseNonOperating | 47.58K | 299.00 | 48.82K | 69.40K |
| InterestIncomeNonOperating | 572.89K | 786.36K | 367.74K | 1.29K |
| OperatingIncome | -15.88M | -19.57M | -27.43M | -33.74M |
| OperatingExpense | 15.88M | 19.57M | 27.43M | 33.74M |
| DepreciationAmortizationDepletionIncomeStatement | 490.57K | 2.51M | 4.54M | 4.05M |
| DepreciationAndAmortizationInIncomeStatement | 490.57K | 2.51M | 4.54M | 4.05M |
| ResearchAndDevelopment | 6.08M | 3.86M | 6.91M | 6.33M |
| SellingGeneralAndAdministration | 9.31M | 13.20M | 15.98M | 23.37M |
| GeneralAndAdministrativeExpense | 9.31M | 13.20M | 15.98M | 23.37M |
| OtherGandA | 6.50M | 7.51M | 14.45M | 15.93M |
| SalariesAndWages | 2.81M | 5.69M | 1.53M | 7.44M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 2.30M | 605.80K | 592.37K | 622.32K |
| ShareIssued | 2.30M | 605.80K | 592.37K | 622.32K |
| TotalDebt | 824.92K | 339.20K | 516.42K | 555.90K |
| TangibleBookValue | 6.55M | 7.88M | 18.50M | 37.93M |
| InvestedCapital | 12.25M | 13.54M | 30.84M | 54.43M |
| WorkingCapital | 5.37M | 6.52M | 10.02M | 37.23M |
| NetTangibleAssets | 6.55M | 7.88M | 18.50M | 37.93M |
| CapitalLeaseObligations | 53.78K | 38.65K | 215.87K | 255.36K |
| CommonStockEquity | 11.48M | 13.24M | 30.54M | 54.13M |
| TotalCapitalization | 11.48M | 13.24M | 30.54M | 54.13M |
| TotalEquityGrossMinorityInterest | 10.44M | 12.91M | 30.54M | 54.13M |
| MinorityInterest | -1.04M | -327.50K | 0.00 | |
| StockholdersEquity | 11.48M | 13.24M | 30.54M | 54.13M |
| OtherEquityInterest | 2.00M | 2.72M | 2.14M | 5.14M |
| GainsLossesNotAffectingRetainedEarnings | 50.80K | 417.34K | 652.60K | 239.61K |
| ForeignCurrencyTranslationAdjustments | 50.80K | 417.34K | 652.60K | 239.61K |
| RetainedEarnings | -172.11M | -157.91M | -144.16M | -126.15M |
| AdditionalPaidInCapital | 31.07M | 30.23M | 28.50M | 22.58M |
| CapitalStock | 150.47M | 137.78M | 143.41M | 152.32M |
| CommonStock | 150.47M | 137.78M | 143.41M | 152.32M |
| TotalLiabilitiesNetMinorityInterest | 6.68M | 4.57M | 7.87M | 8.83M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 | 38.00K | 131.04K |
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 38.00K | 131.04K | |
| LongTermCapitalLeaseObligation | 0.00 | 38.00K | 131.04K | |
| CurrentLiabilities | 6.68M | 4.57M | 7.83M | 8.70M |
| OtherCurrentLiabilities | 492.00K | 31.34K | 243.59K | 765.40K |
| CurrentDeferredLiabilities | 1.00M | 0.00 | ||
| CurrentDeferredRevenue | 1.00M | 0.00 | ||
| CurrentDebtAndCapitalLeaseObligation | 824.92K | 339.20K | 478.42K | 424.86K |
| CurrentCapitalLeaseObligation | 53.78K | 38.65K | 177.87K | 124.31K |
| CurrentDebt | 771.14K | 300.55K | 300.55K | 300.55K |
| OtherCurrentBorrowings | 152.11K | |||
| CurrentNotesPayable | 619.03K | 300.55K | 300.55K | 300.55K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 0.00 | 46.03K | ||
| PayablesAndAccruedExpenses | 4.36M | 4.20M | 7.11M | 7.46M |
| CurrentAccruedExpenses | 1.11M | 954.37K | 4.35M | 4.41M |
| InterestPayable | 409.19K | 409.19K | 409.19K | 364.27K |
| Payables | 3.25M | 3.24M | 2.76M | 3.06M |
| OtherPayable | 59.70K | |||
| AccountsPayable | 3.25M | 3.24M | 2.76M | 3.00M |
| TotalAssets | 17.12M | 17.47M | 38.41M | 62.96M |
| TotalNonCurrentAssets | 5.07M | 6.39M | 20.56M | 17.03M |
| NonCurrentNoteReceivables | 0.00 | 907.37K | 7.43M | 0.00 |
| NonCurrentAccountsReceivable | 907.37K | |||
| InvestmentsAndAdvances | 2.22K | 6.05K | 827.61K | 660.23K |
| OtherInvestments | 2.22K | 6.05K | 827.61K | 660.23K |
| InvestmentinFinancialAssets | 2.22K | 6.05K | ||
| AvailableForSaleSecurities | 2.22K | 6.05K | ||
| GoodwillAndOtherIntangibleAssets | 4.93M | 5.36M | 12.04M | 16.20M |
| OtherIntangibleAssets | 4.93M | 5.36M | 12.04M | 16.20M |
| NetPPE | 130.38K | 120.42K | 260.93K | 168.31K |
| GrossPPE | 130.38K | 120.42K | 260.93K | 168.31K |
| OtherProperties | 130.38K | 120.42K | 260.93K | 168.31K |
| CurrentAssets | 12.05M | 11.09M | 17.85M | 45.93M |
| OtherCurrentAssets | 861.23K | |||
| AssetsHeldForSaleCurrent | 0.00 | 8.65M | ||
| PrepaidAssets | 69.04K | 155.41K | 472.14K | 1.37M |
| Inventory | 117.24K | 0.00 | ||
| FinishedGoods | 65.27K | |||
| RawMaterials | 51.97K | |||
| Receivables | 3.81M | 7.42M | 374.38K | 500.96K |
| OtherReceivables | 7.04K | 3.70K | 228.75K | |
| TaxesReceivable | 367.48K | 209.55K | 279.33K | 272.21K |
| AccruedInterestReceivable | 156.00 | 15.51K | 95.04K | 0.00 |
| LoansReceivable | 3.43M | 7.19M | 0.00 | |
| CashCashEquivalentsAndShortTermInvestments | 7.20M | 3.51M | 17.00M | 35.42M |
| OtherShortTermInvestments | 1.20M | 756.10K | 23.19K | 158.04K |
| CashAndCashEquivalents | 6.00M | 2.76M | 16.98M | 35.26M |
| CashFinancial | 35.26M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -6.88M | -10.83M | -28.70M | -21.25M |
| RepurchaseOfCapitalStock | 0.00 | -2.96M | -1.93M | 0.00 |
| RepaymentOfDebt | -63.59K | -189.05K | -143.07K | -129.32K |
| IssuanceOfDebt | 1.01M | 0.00 | 0.00 | |
| IssuanceOfCapitalStock | 10.67M | 34.00 | 0.00 | 38.34M |
| CapitalExpenditure | -363.96K | -500.00K | ||
| EndCashPosition | 6.00M | 2.76M | 16.98M | 35.26M |
| BeginningCashPosition | 2.76M | 16.98M | 35.26M | 17.52M |
| ChangesInCash | 3.24M | -14.22M | -18.28M | 17.73M |
| FinancingCashFlow | 11.62M | -3.13M | -2.07M | 38.21M |
| CashFromDiscontinuedFinancingActivities | 0.00 | 0.00 | ||
| CashFlowFromContinuingFinancingActivities | 11.62M | -3.13M | -2.07M | 38.21M |
| ProceedsFromStockOptionExercised | 0.00 | 20.25K | 0.00 | 0.00 |
| NetCommonStockIssuance | 10.67M | -2.96M | -1.93M | 38.34M |
| CommonStockPayments | 0.00 | -2.96M | -1.93M | 0.00 |
| CommonStockIssuance | 10.67M | 34.00 | 0.00 | 38.34M |
| NetIssuancePaymentsOfDebt | 948.25K | -189.05K | -143.07K | -129.32K |
| NetShortTermDebtIssuance | 1.01M | 0.00 | 0.00 | -71.76K |
| ShortTermDebtPayments | 0.00 | 0.00 | -71.76K | |
| ShortTermDebtIssuance | 1.01M | 0.00 | 0.00 | |
| NetLongTermDebtIssuance | -63.59K | -189.05K | -143.07K | -57.57K |
| LongTermDebtPayments | -63.59K | -189.05K | -143.07K | -57.57K |
| InvestingCashFlow | -1.50M | -269.58K | 12.12M | 268.96K |
| CashFromDiscontinuedInvestingActivities | 0.00 | 0.00 | 12.73M | 0.00 |
| CashFlowFromContinuingInvestingActivities | -1.50M | -269.58K | -607.53K | 268.96K |
| NetInvestmentPurchaseAndSale | -1.50M | -301.36K | -243.58K | 0.00 |
| SaleOfInvestment | 6.19M | 443.14K | 158.04K | 0.00 |
| PurchaseOfInvestment | -7.69M | -744.50K | -401.61K | 0.00 |
| NetBusinessPurchaseAndSale | 0.00 | 31.78K | 0.00 | 768.96K |
| SaleOfBusiness | 0.00 | 31.78K | 0.00 | 768.96K |
| NetIntangiblesPurchaseAndSale | 0.00 | 0.00 | -250.00K | -500.00K |
| PurchaseOfIntangibles | 0.00 | 0.00 | -250.00K | -500.00K |
| NetPPEPurchaseAndSale | 0.00 | 0.00 | -113.96K | 0.00 |
| PurchaseOfPPE | 0.00 | 0.00 | -113.96K | 0.00 |
| OperatingCashFlow | -6.88M | -10.83M | -28.33M | -20.75M |
| CashFromDiscontinuedOperatingActivities | 0.00 | 0.00 | -1.14M | -1.38M |
| CashFlowFromContinuingOperatingActivities | -6.88M | -10.83M | -27.19M | -19.36M |
| ChangeInWorkingCapital | 9.76M | 1.64M | -7.12M | 2.89M |
| ChangeInOtherWorkingCapital | 1.00M | |||
| ChangeInPayablesAndAccruedExpense | 4.27M | 2.05M | -699.78K | 3.60M |
| ChangeInPayable | 4.27M | 2.05M | -699.78K | 3.60M |
| ChangeInPrepaidAssets | 86.38K | 316.72K | 795.93K | -609.15K |
| ChangeInInventory | -117.24K | 0.00 | 0.00 | |
| ChangeInReceivables | 4.52M | -728.72K | -7.22M | -106.88K |
| OtherNonCashItems | 23.90K | 24.29K | 40.79K | 19.61K |
| StockBasedCompensation | 152.21K | 3.84M | 1.53M | 7.44M |
| UnrealizedGainLossOnInvestmentSecurities | 145.47K | 378.43K | 234.23K | 858.48K |
| AssetImpairmentCharge | 0.00 | 4.56M | 0.00 | 0.00 |
| DepreciationAmortizationDepletion | 490.57K | 2.51M | 4.53M | 4.05M |
| DepreciationAndAmortization | 490.57K | 2.51M | 4.53M | 4.05M |
| Depreciation | 4.05M | |||
| OperatingGainsLosses | -2.53M | -5.53M | 292.84K | -682.51K |
| GainLossOnInvestmentSecurities | -104.48K | -5.15M | -641.26K | -682.51K |
| NetForeignCurrencyExchangeGainLoss | -1.69M | -383.51K | 934.10K | 0.00 |
| NetIncomeFromContinuingOperations | -14.92M | -18.23M | -26.70M | -33.94M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for QNTM
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|